Health Minister Mandaviya addresses Bharat Swaasth Mahotsav
Bharat Swasth Mahotsav organises ‘Padma Doctors Congregation’ for Celebrating Healthcare Changemakers in India Since Independence
Bharat Swasth Mahotsav organises ‘Padma Doctors Congregation’ for Celebrating Healthcare Changemakers in India Since Independence
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 70.59 crores during the period ended June 30, 2022.
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Investment in response to increased demand for North American-based chemistry services
Subscribe To Our Newsletter & Stay Updated